Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)

Optimism hos Astra Zeneca – ”Ökande efterfrågan i alla nyckelregioner”

Astra Zeneca överraskade positivt när bolaget redovisade resultaten för fjolårets fjärde kvartal. Samtidigt kom information om att bolaget har obetalda skatter i Kina.

Chiesi satsar på leverinriktad genterapi

Läkemedelsbolaget Chiesi tar ytterligare kliv in på genterapiområdet genom ett licensavtal med amerikanska Arbor Biotechnologies.

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

Conjugate Planes in Microscopy

Knowledge Article from ZEISS.

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Novo Nordisk skrotar distansarbete

Vid årsskiftet slopar Novo Nordisk möjligheten till distansarbete. Enligt bolagets nya vd ska det påskynda beslutsfattandet och förbättra den kommersiella genom...

The FDA’s new transparency policy (Part 3)

As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

Efter förseningen – nu lämnar Xspray in uppdaterad FDA-ansökan

Forskningsbolaget Xspray Pharma har nu lämnat in en uppdaterad FDA-ansökan om godkännande för leukemibehandlingen Dasynoc.

Elevating 3D characterization with enhanced performance and efficiencies

Introducing the ZEISS VersaXRM 730 3D X-ray microscope.

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Revealing the secrets of a part

CT inspection in automation technology at Festo.

WHO: Pandemiavtal klart

Tre år av förhandlingar har lett fram till ett utkast på ett avtal som ska göra världen bättre förberedd på framtida pandemier.

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Även Sanofi pausar brittiska investeringar

Sanofi går i flera andra läkemedelsjättars fotspår och fryser alla investeringsbeslut om forskning och utveckling i Storbritannien.

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Klartecken för Pharmnovo – kan gå vidare med studie i nervsmärta

Pharmnovo har fått godkännande från spanska myndigheter att genomföra en fas IIa-studie för att pröva bolagets läkemedelskandidat för behandling av neuropatisk smärta.

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...